Logotype for ProMIS Neurosciences Inc

ProMIS Neurosciences (PMN) Registration Filing summary

Event summary combining transcript, slides, and related documents.

Logotype for ProMIS Neurosciences Inc

Registration Filing summary

18 Mar, 2026

Company overview and business model

  • Applies a patented technology platform to develop antibody therapies and vaccines for neurodegenerative and protein-misfolding diseases, focusing on Alzheimer's, MSA, and ALS.

  • Pipeline includes PMN310 (lead, targeting amyloid-beta in Alzheimer's, in Phase 1b), PMN267 (targeting TDP-43 in ALS), and PMN442 (targeting a-synuclein in synucleinopathies).

  • Platform leverages protein biology, physics, and supercomputing to selectively target toxic misfolded proteins.

  • Operations have been funded primarily through public and private placements of shares, warrants, and convertible debt.

Financial performance and metrics

  • Raised approximately $75.5 million in gross proceeds from a private placement in January 2026.

  • 6,090,075 shares sold at $10.77 each, 725,221 shares at $12.13 to affiliates/insiders, and 100,000 pre-funded warrants at $10.77 less $0.0001 exercise price.

Use of proceeds and capital allocation

  • Proceeds from warrant exercises, if any, will be used to advance clinical development of PMN310, for working capital, and general corporate expenses.

  • No assurance that any warrants will be exercised; company will not receive proceeds from resale of shares by selling securityholders.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more